Related Experiment Video
Updated: Jun 22, 2026

Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
Early Staphylococcal Periprosthetic Joint Infection (PJI) Treated with Debridement, Antibiotics, and Implant
Hannah K Eriksson1, Stergios Lazarinis1, Josef D Järhult2
1Department of Surgical Sciences, Section of Orthopaedics, Uppsala University, 751 83 Uppsala, Sweden.
Abstract:
It is unknown how rifampicin resistance in staphylococci causing a periprosthetic joint infection (PJI) affects outcomes after debridement, antibiotics, and implant retention (DAIR). We thus aimed to compare the risk of relapse in DAIR-treated early PJI caused by staphylococci with or without rifampicin resistance. In total, 81 patients affected by early PJI were included, and all patients were treated surgically with DAIR. This was repeated if needed. The endpoint of relapse-free survival was estimated using the Kaplan-Meier method, and Cox regression models were fitted to assess the risk of infection relapse for patients infected with rifampicin-resistant bacteria, adjusted for age, sex, type of joint, and type of index surgery. In patients with rifampicin-resistant staphylococci, relapse was seen in 80% after one DAIR procedure and in 70% after two DAIR procedures. In patients with rifampicin-sensitive bacteria, 51% had an infection relapse after one DAIR procedure and 33% had an infection relapse after two DAIR procedures. Patients with rifampicin-resistant staphylococcal PJI thus had an increased adjusted risk of infection relapse of 1.9 (95% CI: 1.1-3.6, p = 0.04) after one DAIR procedure compared to patients with rifampicin-sensitive bacteria and a 4.1-fold (95% CI: 1.2-14.1, p = 0.03) increase in risk of infection relapse after two DAIR procedures. Staphylococcal resistance to rifampicin is associated with inferior outcomes after DAIR. These findings suggest that DAIR may not be a useful strategy in early PJI caused by rifampicin-resistant staphylococci.
Insights
Rifampicin resistance in staphylococci significantly increases the risk of relapse in patients with early periprosthetic joint infection (PJI) treated with debridement, antibiotics, and implant retention (DAIR). This suggests DAIR may be ineffective for PJI caused by resistant strains.
Area of Science:
- Orthopedics
- Infectious Diseases
- Microbiology
Background:
- Periprosthetic joint infection (PJI) is a serious complication following joint replacement surgery.
- Staphylococcal infections are a common cause of PJI.
- The impact of rifampicin resistance in staphylococci on PJI treatment outcomes remains unclear.
Purpose of the Study:
- To compare the risk of infection relapse in early PJI patients treated with debridement, antibiotics, and implant retention (DAIR).
- To evaluate outcomes based on whether the causative staphylococci were resistant or sensitive to rifampicin.
Main Methods:
- Retrospective analysis of 81 patients with early PJI treated with DAIR.
- Relapse-free survival estimated using Kaplan-Meier method.
- Cox regression models used to assess the adjusted risk of infection relapse.
Main Results:
- Patients with rifampicin-resistant staphylococci had higher relapse rates: 80% after one DAIR, 70% after two.
- Patients with rifampicin-sensitive bacteria had lower relapse rates: 51% after one DAIR, 33% after two.
- Rifampicin resistance increased the adjusted risk of relapse by 1.9-fold after one DAIR and 4.1-fold after two DAIR procedures (p < 0.05).
Conclusions:
- Staphylococcal resistance to rifampicin is linked to poorer outcomes in DAIR treatment for PJI.
- DAIR may not be a suitable treatment strategy for early PJI caused by rifampicin-resistant staphylococci.
- Further research into alternative treatment strategies for resistant PJI is warranted.
Related Concept Videos
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Staphylococcal Skin Infections
Clinical Significance of Antibiotic Resistance

